caa a22 4500 477072372 CHVBK 20180405111429.0 cr unu---uuuuu 170330e19960901xx s 000 0 eng 10.1007/BF00051104 doi (NATIONALLICENCE)springer-10.1007/BF00051104 Lichtlen Paul Hannover Medical School, Hannover, Germany aut Controversies concerning calcium antagonists [Elektronische Daten] [Paul Lichtlen] Summary: The paper discusses the controversial attitude regarding the safety of calcium channel blockers (CCBs), especially of the dihydropyridine nifedipine, induced through several meta-analyses of studies with CCBs by Dr. Furberg et al.; as a result, a detrimental effect of CCBs, especially during acute myocardial infarction, has been claimed. Several independent re-analyses of the 16 studies, all performed in the 1980s and mainly using the short-acting nifedipine capsule, did not confirm Furberg's results and showed an insignificant mortality difference between patients on CCBs versus those on control. Nevertheless, new safety studies applying long-acting CCBs (half-lives of 1 or more days) combined with efficacy assessments are necessary, both in hypertension as well as coronary artery disease, to finally clear up this important question. Kluwer Academic Publishers, 1986 calcium channel blockers nationallicence hypertension nationallicence coronary disease nationallicence acute myocardial infarction nationallicence nifedipine nationallicence Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10/4(1996-09-01), 409-412 0920-3206 10:4<409 1996 10 10557 https://doi.org/10.1007/BF00051104 text/html Onlinezugriff via DOI 1 editorial jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00051104 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Lichtlen Paul Hannover Medical School, Hannover, Germany aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10/4(1996-09-01), 409-412 0920-3206 10:4<409 1996 10 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer